M

oderna Therapeutics, biotech’s highest-profile and most richly funded startup, is losing another key executive, struggling to retain talent despite the company’s unwavering promise that it’s on pace to change the face of medicine.

Dr. Stephen Kelsey, head of Moderna’s oncology division, is leaving the company to work at a biotech startup in California, according to people familiar with the matter. Each spoke on condition of anonymity, citing strict nondisclosure agreements.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy